Veritas Investment Management LLP lifted its holdings in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 7.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 411,854 shares of the medical research company’s stock after buying an additional 27,192 shares during the quarter. Thermo Fisher Scientific comprises 10.5% of Veritas Investment Management LLP’s investment portfolio, making the stock its 3rd biggest position. Veritas Investment Management LLP owned about 0.11% of Thermo Fisher Scientific worth $71,866,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Proficio Capital Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 71.5% during the 1st quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after buying an additional 253 shares in the last quarter. Cribstone Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 8.7% during the 2nd quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after buying an additional 50 shares in the last quarter. Shine Investment Advisory Services Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $113,000. Chicago Partners Investment Group LLC purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $108,000. Finally, CWM LLC lifted its stake in shares of Thermo Fisher Scientific by 17.0% during the 2nd quarter. CWM LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after buying an additional 103 shares in the last quarter. Institutional investors own 83.36% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/veritas-investment-management-llp-increases-position-in-thermo-fisher-scientific-inc-tmo/1627280.html.

In other news, Director C Martin Harris sold 360 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total transaction of $65,149.20. Following the sale, the director now owns 5,312 shares in the company, valued at $961,312.64. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Gregory J. Herrema sold 30,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $176.02, for a total transaction of $5,280,600.00. Following the sale, the senior vice president now owns 67,016 shares in the company, valued at approximately $11,796,156.32. The disclosure for this sale can be found here. In the last quarter, insiders have sold 52,738 shares of company stock worth $9,302,112. Company insiders own 0.49% of the company’s stock.

TMO has been the topic of a number of recent research reports. Bank of America Corporation restated a “buy” rating and set a $210.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Friday, July 21st. Cleveland Research upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. Citigroup Inc. restated a “buy” rating and set a $201.00 price target (up from $182.00) on shares of Thermo Fisher Scientific in a research note on Monday, July 10th. BidaskClub cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 27th. Finally, Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $199.00 price target on the stock in a research note on Tuesday, July 11th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $203.64.

Thermo Fisher Scientific Inc (NYSE TMO) opened at 193.39 on Friday. The stock has a 50 day moving average of $188.78 and a 200-day moving average of $174.98. The company has a market cap of $75.45 billion, a price-to-earnings ratio of 33.69 and a beta of 1.05. Thermo Fisher Scientific Inc has a one year low of $139.07 and a one year high of $194.30.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.03. The firm had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.03 earnings per share. On average, equities analysts predict that Thermo Fisher Scientific Inc will post $9.35 EPS for the current fiscal year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.